180 related articles for article (PubMed ID: 35163672)
1. Nanocarrier-Based Delivery of SN22 as a Tocopheryl Oxamate Prodrug Achieves Rapid Tumor Regression and Extends Survival in High-Risk Neuroblastoma Models.
Alferiev IS; Guerrero DT; Soberman D; Guan P; Nguyen F; Kolla V; Fishbein I; Pressly BB; Brodeur GM; Chorny M
Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163672
[TBL] [Abstract][Full Text] [Related]
2. Structural Optimization and Enhanced Prodrug-Mediated Delivery Overcomes Camptothecin Resistance in High-Risk Solid Tumors.
Nguyen F; Guan P; Guerrero DT; Kolla V; Naraparaju K; Perry LM; Soberman D; Pressly BB; Alferiev IS; Chorny M; Brodeur GM
Cancer Res; 2020 Oct; 80(19):4258-4265. PubMed ID: 32839252
[TBL] [Abstract][Full Text] [Related]
3. Nanoparticle-mediated delivery of a rapidly activatable prodrug of SN-38 for neuroblastoma therapy.
Alferiev IS; Iyer R; Croucher JL; Adamo RF; Zhang K; Mangino JL; Kolla V; Fishbein I; Brodeur GM; Levy RJ; Chorny M
Biomaterials; 2015 May; 51():22-29. PubMed ID: 25770994
[TBL] [Abstract][Full Text] [Related]
4. Poloxamer-linked prodrug of a topoisomerase I inhibitor SN22 shows efficacy in models of high-risk neuroblastoma with primary and acquired chemoresistance.
Alferiev IS; Guerrero DT; Guan P; Nguyen F; Kolla V; Soberman D; Pressly BB; Fishbein I; Brodeur GM; Chorny M
FASEB J; 2022 Mar; 36(3):e22213. PubMed ID: 35192728
[TBL] [Abstract][Full Text] [Related]
5. Enhanced Intratumoral Delivery of SN38 as a Tocopherol Oxyacetate Prodrug Using Nanoparticles in a Neuroblastoma Xenograft Model.
Nguyen F; Alferiev I; Guan P; Guerrero DT; Kolla V; Moorthy GS; Chorny M; Brodeur GM
Clin Cancer Res; 2018 Jun; 24(11):2585-2593. PubMed ID: 29514842
[No Abstract] [Full Text] [Related]
6. Nanoparticle delivery of an SN38 conjugate is more effective than irinotecan in a mouse model of neuroblastoma.
Iyer R; Croucher JL; Chorny M; Mangino JL; Alferiev IS; Levy RJ; Kolla V; Brodeur GM
Cancer Lett; 2015 May; 360(2):205-12. PubMed ID: 25684664
[TBL] [Abstract][Full Text] [Related]
7. Tumor regression and curability of preclinical neuroblastoma models by PEGylated SN38 (EZN-2208), a novel topoisomerase I inhibitor.
Pastorino F; Loi M; Sapra P; Becherini P; Cilli M; Emionite L; Ribatti D; Greenberger LM; Horak ID; Ponzoni M
Clin Cancer Res; 2010 Oct; 16(19):4809-21. PubMed ID: 20702613
[TBL] [Abstract][Full Text] [Related]
8. TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts.
Croucher JL; Iyer R; Li N; Molteni V; Loren J; Gordon WP; Tuntland T; Liu B; Brodeur GM
Cancer Chemother Pharmacol; 2015 Jan; 75(1):131-41. PubMed ID: 25394774
[TBL] [Abstract][Full Text] [Related]
9. Integrating a novel SN38 prodrug into the PEGylated liposomal system as a robust platform for efficient cancer therapy in solid tumors.
Fang T; Dong Y; Zhang X; Xie K; Lin L; Wang H
Int J Pharm; 2016 Oct; 512(1):39-48. PubMed ID: 27544846
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of anticancer efficacy using modified lipophilic nanoparticle drug encapsulation.
Lee P; Zhang R; Li V; Liu X; Sun RW; Che CM; Wong KK
Int J Nanomedicine; 2012; 7():731-7. PubMed ID: 22359452
[TBL] [Abstract][Full Text] [Related]
11. Encapsulation and Controlled Release of a Camptothecin Prodrug from Nanocarriers and Microgels: Tuning Release Rate with Nanocarrier Excipient Composition.
Wilson BK; Sinko PJ; Prud'homme RK
Mol Pharm; 2021 Mar; 18(3):1093-1101. PubMed ID: 33440941
[TBL] [Abstract][Full Text] [Related]
12. Dynamic core crosslinked camptothecin prodrug micelles with reduction sensitivity and boronic acid-mediated enhanced endocytosis: An intelligent tumor-targeted delivery nanoplatform.
Huang Y; Zhang W; Xu Y; Zhu S; Wu Y; Chen T; Xiao Y; Lu W; Zhang X; Yu J
Int J Pharm; 2020 Apr; 580():119250. PubMed ID: 32209369
[TBL] [Abstract][Full Text] [Related]
13. Bifunctional supramolecular prodrug vesicles constructed from a camptothecin derivative with a water-soluble pillar[5]arene for cancer diagnosis and therapy.
Sun G; He Z; Hao M; Xu Z; Hu XY; Zhu JJ; Wang L
Chem Commun (Camb); 2019 Sep; 55(73):10892-10895. PubMed ID: 31436766
[TBL] [Abstract][Full Text] [Related]
14. A water soluble prodrug of a novel camptothecin analog is efficacious against breast cancer resistance protein-expressing tumor xenografts.
Endo M; Miwa M; Ura M; Tanimura H; Taniguchi K; Miyazaki Y; Ohwada J; Tsukazaki M; Niizuma S; Murata T; Ozawa S; Suda H; Ogawa K; Nanba E; Nagao S; Shimma N; Yamada-Okabe H
Cancer Chemother Pharmacol; 2010 Jan; 65(2):363-71. PubMed ID: 19495753
[TBL] [Abstract][Full Text] [Related]
15. A self-immolative prodrug nanosystem capable of releasing a drug and a NIR reporter for in vivo imaging and therapy.
Wang Z; Wu H; Liu P; Zeng F; Wu S
Biomaterials; 2017 Sep; 139():139-150. PubMed ID: 28614754
[TBL] [Abstract][Full Text] [Related]
16. Redox-responsive amphiphilic camptothecin prodrug nanoparticles for targeted liver tumor therapy.
Lu L; Li B; Lin C; Li K; Liu G; Xia Z; Luo Z; Cai K
J Mater Chem B; 2020 May; 8(17):3918-3928. PubMed ID: 32227058
[TBL] [Abstract][Full Text] [Related]
17. A chemical screen identifies the chemotherapeutic drug topotecan as a specific inhibitor of the B-MYB/MYCN axis in neuroblastoma.
Sottile F; Gnemmi I; Cantilena S; D'Acunto WC; Sala A
Oncotarget; 2012 May; 3(5):535-45. PubMed ID: 22619121
[TBL] [Abstract][Full Text] [Related]
18. De novo engineering of both an omega-3 fatty acid-derived nanocarrier host and a prodrug guest to potentiate drug efficacy against colorectal malignancies.
Chen X; Cui L; Xu J; Xian S; Meng F; Zhan C; Wang H
Biomaterials; 2022 Nov; 290():121814. PubMed ID: 36194953
[TBL] [Abstract][Full Text] [Related]
19. A Novel Nanomicellar Combination of Fenretinide and Lenalidomide Shows Marked Antitumor Activity in a Neuroblastoma Xenograft Model.
Orienti I; Nguyen F; Guan P; Kolla V; Calonghi N; Farruggia G; Chorny M; Brodeur GM
Drug Des Devel Ther; 2019; 13():4305-4319. PubMed ID: 31908416
[TBL] [Abstract][Full Text] [Related]
20. Hydrophobically modified glycol chitosan nanoparticles-encapsulated camptothecin enhance the drug stability and tumor targeting in cancer therapy.
Min KH; Park K; Kim YS; Bae SM; Lee S; Jo HG; Park RW; Kim IS; Jeong SY; Kim K; Kwon IC
J Control Release; 2008 May; 127(3):208-18. PubMed ID: 18336946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
